Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
NCT06967480 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2026-02-05
Summary
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
Conditions
- Generalized Myasthenia Gravis
- Anti-AChR Antibody Positive
Interventions
- DRUG
-
Ravulizumab
Participants will receive Ravulizumab.
Sponsors & Collaborators
-
Alexion Pharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-31
- Primary Completion
- 2027-06-30
- Completion
- 2027-06-30
- FDA Drug
- Yes
Countries
- Italy
Study Locations
More Related Trials
-
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT03971422 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
NCT03863080 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT04124965 ·Status: COMPLETED ·Phase: PHASE3
-
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
NCT06381284 ·Status: COMPLETED
-
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
NCT06540144 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920 ·Status: RECRUITING ·Phase: PHASE3
-
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
NCT05868837 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis
NCT05132569 ·Status: TERMINATED ·Phase: PHASE3
-
Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis
NCT07071246 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
NCT06764160 ·Status: COMPLETED ·Phase: PHASE3
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
NCT02609022 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
NCT00619671 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
NCT03052751 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
NCT07246564 ·Status: RECRUITING ·Phase: PHASE4
-
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
NCT03315130 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
NCT06149559 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
NCT04201262 ·Status: COMPLETED ·Phase: PHASE3
-
The Evaluation of Belimumab in Myasthenia Gravis (MG)
NCT01480596 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis
NCT03165435 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
NCT06909214 ·Status: RECRUITING ·Phase: PHASE4
-
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170 ·Status: RECRUITING
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916 ·Status: RECRUITING ·Phase: PHASE3
-
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT03669588 ·Status: COMPLETED ·Phase: PHASE3